Two drugmakers filed an emergency appeal to the U.S. Supreme Court on Saturday to restore mail-order access to the abortion medication mifepristone [1].
The legal move follows a Friday ruling by the U.S. Court of Appeals for the 5th Circuit [2] that ended telemedicine access to the drug. This development could restrict access to reproductive healthcare even in states where abortion remains legal [3].
Among the companies filing the appeal is Danco Laboratories [1]. The two companies seek to pause the lower-court order that prohibits the distribution of the medication via mail, and telemedicine services [1].
The 5th Circuit ruling created a nationwide restriction on how the drug is delivered to patients [2]. By appealing to the highest court, the manufacturers aim to prevent a systemic shift in how mifepristone is accessed across the country [3].
The emergency appeal focuses on the immediate need to maintain the status quo of telemedicine access while the broader legal challenge proceeds [1]. The manufacturers said the lower-court ruling creates an undue burden on patients who rely on mail-order pharmacy services [3].
The U.S. Supreme Court must now decide whether to grant the emergency stay, which would temporarily reinstate the ability for providers to prescribe and mail mifepristone to patients [2].
“Two drugmakers filed an emergency appeal to the U.S. Supreme Court on Saturday to restore mail-order access to the abortion medication mifepristone.”
This legal battle highlights a growing conflict between regional judicial rulings and national healthcare delivery. If the Supreme Court denies the appeal, it would effectively establish a nationwide ban on the telemedicine distribution of mifepristone, regardless of individual state laws, fundamentally altering the landscape of reproductive health access in the U.S.
